Table 5 Overview of baseline characteristics per included study
Author | Shahab D | Zhou | Geva R | Gamaleldin M | Kuan FC | Kiran RP | Hu X | CAPIRCI C | Dossa F |
|---|---|---|---|---|---|---|---|---|---|
Year | 2017 | 2016 | 2014 | 2017 | 2017 | 2012 | 2019 | 2008 | 2018 |
Country | USA | China | Israel | USA | China | USA | China | Italy | Canada |
Study design | Retrospective | Case control | Case control | Prospective control | Case control | Case control | Case control | Prospective sub-group | Retrospective |
N | 789/2102 | 19/21 | 35/17 | 47/83 | 114/145 | 14/34 | 115/56 | 127/439 | 667/667 |
Age (c/n) | 57.2/61.2 | 54/54.1 | 60.9/68.7 | 55.9/60.6 | 56.7/61.8 | 50.5/55.5 | 54.5/57.6 | 62 | 56/57 |
Gender (male%) | 56.8/61.2 | 36.8/76.2 | 68.5/47 | 57.4/67.5 | 59.6/66.2 | 50/73.5 | 67.8/57.8 | 67 | 56.8/55.5 |
cT-stage | |||||||||
T1–2 | 110/348 | 2/2 | 1/2 | NA | 11/21 | 1/4 | 57/23 | 29 | 60/59 |
T3–4 | 679/1754 | 17/19 | 31/14 | NA | 102/124 | 13/30 | 58/33 | 409 | 585/584 |
cN-stage | |||||||||
N0 | 388/1224 | 6/7 | 23/12 | 25/48 | 33/52 | 9/22 | 66/31 | NA | 319/319 |
N+ | 401/878 | 10/12 | 9/3 | 22/34 | 81/91 | 5/12 | 49/25 | 169 | 348/348 |
Surgery | |||||||||
AR | 565/1474 | 16/12 | 26/10 | 5/41 | 78/108 | 12/22 | 69/25 | 339 | NA |
APR | 183/511 | 3/9 | 9/7 | 42/13 | 15/16 | 2/12 | 46/31 | 100 | NA |
Chemotherapy regimen | NA | Combined and single-agent | NA | NA | NA | NA | Combined and single-agent | Combined and single-agent | NA |